AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

Spin-Out From UK’s Antibody Taskforce

 
• By Andrew McConaghie

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

AstraZeneca Cambridge
Following its COVID-19 success, AstraZeneca has created a new division to commercialize vaccines and antibody therapies. • Source: AstraZeneca

More from Deals

More from Business